Lineage Cell Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Lineage Cell Therapeutics, Inc. (LCTX) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$7.96 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-06
- Lineage Cell Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$7.96M.
- Lineage Cell Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$7.14M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month |
|---|---|---|
| 2026-06-30 | -$7.96M 10-Q · filed 2026-08-06 | -$15.10M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$7.14M 10-Q · filed 2026-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |